Skip to content

Assessment of the Glycemic Responses to Nutritional Products-INQ-2526

Determination of the Postprandial Glycemic Response and Glycemic Index of Nutritional Products: A Randomized Controlled Clinical Trial in Healthy Individuals

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07243743
Acronym
GLIN#5
Enrollment
14
Registered
2025-11-24
Start date
2025-10-17
Completion date
2025-12-03
Last updated
2026-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glycemic Response

Keywords

Glycemic response, Glycemic Index, nutritional products, healthy individuals

Brief summary

This study assesses the glycemic responses to nutritional products. During a study visit fasted subjects will consume a serving of the reference product or the test product. Capillary blood samples will be taken at baseline and at several time-points over a 2-hr period. Several nutritional products will be tested over time.

Interventions

DIETARY_SUPPLEMENTFirst Reference Product

dextrose (containing 10 grams of carbohydrates)

DIETARY_SUPPLEMENTSecond Reference Product

dextrose (containing 10 grams of carbohydrates)

DIETARY_SUPPLEMENTThird Reference Product

dextrose (containing 10 grams of carbohydrates)

DIETARY_SUPPLEMENTFirst Concept Product

high protein beverage no sugar 1

DIETARY_SUPPLEMENTSecond Concept Product

high protein beverage no sugar 2

Sponsors

Nutricia Research
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
NONE

Intervention model description

2 test products and 3 controls, in total 5 products

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

1. Age ≥ 18 and ≤ 65 years 2. Body mass index (BMI) between 18.5 and 27 kg/m²

Exclusion criteria

1. Fasting Glucose ≥6.1 at screening visit 2. Known history of gastrointestinal disease, bariatric surgery, AIDS, hepatitis, a history or presence of clinically important endocrine (including Type 1 or Type 2 diabetes mellitus), or any condition which might, in the opinion of the medical director either: 1) make participation dangerous to the subject or to others, or 2)affect the results. 3. Use of medications known to influence carbohydrate metabolism, gastrointestinal function or appetite, including, but not limited to adrenergic blockers, diuretics, thiazolidinediones, metformin and systemic corticosteroids within 4 weeks of the screening visit, or any medication which might, in the opinion of the medical director either: 1) make participation dangerous to the subject or to others, or 2) affect the results. 4. Major trauma or surgical event within 3 months of screening. 5. Known intolerance, sensitivity or allergy to test products. 6. Extreme dietary habits, as judged by the Investigator (i.e. Atkins diet, very high protein diets, etc.). 7. History of cancer in the prior two years, except for non-melanoma skin cancer.

Design outcomes

Primary

MeasureTime frame
The glycemic index of nutritional productsFrom enrollment to the end of treatment at about 6 weeks

Secondary

MeasureTime frame
1. The postprandial glucose levels at each time point after each test product compared with the mean of the 3 referencesFrom enrollment to the end of treatment at about 6 weeks
2. The postprandial incremental area under the curve (iAUC) after each test product compared with the mean of the 3 referencesFrom enrollment to the end of treatment at about 6 weeks

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 2, 2026